QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

The goal of this study is to learn more about the efficacy and safety of BMS-986363 in participants with relapsed or refractory multiple myeloma. 

Trial status

Accepting patients

Phase
Phase 2
Enrollment
150
Last Updated
3 days ago
Patient Screener

Participating Centers

There are 37 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BMS-986393 (CC-95266) is an investigational study medicine that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize myeloma tumor cells more easily.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

BMS-986393

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.